Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26038893 | 0.86 | FOLH1 (0.44) | FOLH1ANPEPENPEP | |
| SCHEMBL21578076 | 0.84 | FOLH1 (0.48) | FOLH1ANPEPENPEPACACBKMT2A | |
| SCHEMBL20179172 | 0.82 | FOLH1 (0.67) | FOLH1ANPEPENPEPACACBKMT2A | |
| SCHEMBL20168587 | 0.77 | FOLH1 (0.50) | FOLH1ANPEPENPEPACACBKMT2A | |
| SCHEMBL26038808 | 0.76 | FOLH1 (0.76) | FOLH1ANPEPENPEPTDP1 | |
| SCHEMBL26038895 | 0.75 | FOLH1 (0.45) | FOLH1ANPEPENPEP | |
| SCHEMBL20179169 | 0.75 | FOLH1 (0.43) | FOLH1ANPEPENPEP | |
| SCHEMBL20179164 | 0.74 | ANPEP (0.43) | FOLH1ANPEPENPEPKMT2AALDH1A1 | |
| SCHEMBL26038897 | 0.74 | FOLH1 (0.44) | FOLH1ANPEPENPEP | |
| SCHEMBL2494105 | 0.74 | ANPEP (0.46) | FOLH1ANPEPENPEPKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154939-A2 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | FOLH1 39/4885ANPEP 1063/4885ENPEP 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.